The Shape of Covid Mutations to Come By Brian Simpson

With the emergence, rapidly it is supposed by the mainstream, of the Covid variant, Omicron, conspiracies aside, which could be true (i.e. this one was also cooked up in a bioweapons lab and released to keep the covid tyranny going), the issue of why arises. As I have pointed out many times, “leaky” vaccines, which don ot kill of the virus totally may lead to selection pressure being placed upon the virus to mutate to survive. This idea has been advanced by Dr. Geert Vanden Bossche, a vaccinologist who worked with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle and Global Alliance for Vaccines and Immunization in Geneva, as detailed below.

 

https://childrenshealthdefense.org/defender/vaers-cdc-omicron-vaccine-makers-stock-adverse-events-deaths/?utm_source=salsa&eType=EmailBlastContent&eId=7a598880-92c9-4137-990f-64192b91d6f6

COVID vaccine stocks surge amid fears of new omicron variant

Shares of major COVID vaccine makers surged amid the latest pandemic fears surrounding the new Omicron variant, CNN Business reported.

Moderna climbed more than 20% during Black Friday’s short trading session on Wall Street and increased by an additional 10% on Monday.

Shares of BioNTech, which partners with Pfizer to produce COVID vaccines, soared 14% on Friday and were up 3% Monday, as Pfizer gained 6% Friday.

Investors are hoping the vaccine makers will be able to quickly update their COVID vaccines to offer protection for the Omicron variant.

Moderna said Friday it “will rapidly advance an Omicron-specific booster candidate” while Pfizer said it hoped to have an update of its vaccine ready in 100 days if Omicron shows resistance to its current vaccine.

Moderna CEO predicts reduction in COVID vaccine effectiveness against Omicron variant

Stéphane Bancel, CEO of Moderna, said in an interview Tuesday current COVID vaccines will likely be much less effective against the new Omicron variant, compared with previous variants, The Washington Post reported.

“I just don’t know how much, because we need to wait for the data,” Bancel said. “But all the scientists I’ve talked to … are, like, ‘This is not going to be good.’”

Bancel said scientists did not expect such a highly mutative variant to emerge for another year or two, noting 32 of the 50 mutations in Omicron involve the spike protein — the area targeted by existing COVID vaccines.

In early March, Dr. Geert Vanden Bossche, a vaccinologist who worked with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle and Global Alliance for Vaccines and Immunization in Geneva, broke down the dangers of mass vaccination for COVID compared to natural infection and concluded:

“There can be no doubt that continued mass vaccination campaigns will enable new, more infectious viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete resistance of circulating variants to the current vaccines.”

As The Defender reported March 26, a combination of lockdowns and extreme selection pressure on the virus induced by the intense global mass vaccination program, might diminish the number of cases, hospitalizations and deaths in the short-term, but will ultimately induce the creation of more mutants of concern.

This is the result of what Vanden Bossche called “immune escape,” which will in turn trigger vaccine companies to further refine vaccines that will add to, not reduce, the selection pressure, producing ever more transmissible and potentially deadly variants.

Vanden Bossche argued the selection pressure would cause greater convergence in SARS-CoV-2 mutations affecting the spike protein of the virus responsible for breaking through the mucosal surfaces of our airways — the route used by the virus to enter the human body — effectively outsmarting the highly specific antigen-based vaccines that are being used and tweaked, dependent on the circulating variants.”

 

 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Saturday, 04 May 2024

Captcha Image